 |
| As
drug developers face the ever-pressing need to get molecules to market
as efficiently as possible, firms large and small are increasingly
turning to CDMOs for help. The CDMO industry is evolving to meet this
need, spurring some larger providers to offer forward-thinking services
in the form of end-to-end supply chain models for pharmaceutical and
biopharmaceutical clients. At a panel discussion held at CPhI North
America 2017 in Philadelphia, four industry experts discussed how
working with a single-source CDMO partner can accelerate time to market,
add cost savings, and improve a formulation’s chances of achieving
regulatory success. |
|
